Sparrow Pharmaceuticals Raises $95M Series B for Midstage Diabetes Study on September 25, 2025 Capital Management clofutriben Diabetes Mellitus, Non-Insulin-Dependent Forbion hydrocortisone Psychological inhibition Rheumatoid Arthritis Series B fundraising SPAG8 gene Sparrow Pharmaceuticals venture +
Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset on March 18, 2025 Bioscience hydrocortisone Vision +